Search research articles
Contact Us
Filters
Showing results (1-10 of 34) with videos related to
Page
of 4
Sort By:
British Journal of Clinical Pharmacology
|
December 29, 2021
Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors
Wajd Alkabbani, John-Michael Gamble
Drug Design, Development and Therapy
|
July 21, 2021
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
Wajd Alkabbani, John-Michael Gamble
Canadian Journal of Diabetes
|
December 8, 2022
Prescribing Trends of the Sodium-Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015-2021)
Wajd Alkabbani, John-Michael Gamble
Drug Safety
|
June 17, 2022
Authors' Reply to Noguchi's comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data."
John-Michael Gamble, Wajd Alkabbani
Annals of Internal Medicine
|
January 19, 2026
Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?
Robert M Centor, Wajd Alkabbani
Drug Safety
|
April 15, 2023
Author's Reply to Kuss and Rathmann's Comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"
John-Michael Gamble, Wajd Alkabbani
Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC
|
December 7, 2020
Cannabis is legal-why are cannabis-based pharmaceuticals still controlled?
Wajd Alkabbani, Kevin Friesen, Shawn Bugden
American Journal of Medicine Open
|
July 22, 2024
Peak performance: Putting type 1 diabetes management recommendations for athletes to the test
Bradley Grightmire, Wajd Alkabbani, John-Michael Gamble
American Journal of Epidemiology
|
March 22, 2021
Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events
Wajd Alkabbani, Ryan Pelletier, John-Michael Gamble
JAMA Ophthalmology
|
October 23, 2025
Neovascular Age-Related Macular Degeneration and GLP-1 RAs
Wajd Alkabbani, Sara J Cromer, Elisabetta Patorno
Page
of 4
Search research articles
Search
Showing results (1-10 of 34) with videos related to
Sort By:
Page
of 4
British Journal of Clinical Pharmacology
|
December 29, 2021
Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors
Wajd Alkabbani, John-Michael Gamble
Drug Design, Development and Therapy
|
July 21, 2021
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
Wajd Alkabbani, John-Michael Gamble
Canadian Journal of Diabetes
|
December 8, 2022
Prescribing Trends of the Sodium-Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015-2021)
Wajd Alkabbani, John-Michael Gamble
Drug Safety
|
June 17, 2022
Authors' Reply to Noguchi's comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data."
John-Michael Gamble, Wajd Alkabbani
Annals of Internal Medicine
|
January 19, 2026
Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?
Robert M Centor, Wajd Alkabbani
Drug Safety
|
April 15, 2023
Author's Reply to Kuss and Rathmann's Comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"
John-Michael Gamble, Wajd Alkabbani
Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC
|
December 7, 2020
Cannabis is legal-why are cannabis-based pharmaceuticals still controlled?
Wajd Alkabbani, Kevin Friesen, Shawn Bugden
American Journal of Medicine Open
|
July 22, 2024
Peak performance: Putting type 1 diabetes management recommendations for athletes to the test
Bradley Grightmire, Wajd Alkabbani, John-Michael Gamble
American Journal of Epidemiology
|
March 22, 2021
Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events
Wajd Alkabbani, Ryan Pelletier, John-Michael Gamble
JAMA Ophthalmology
|
October 23, 2025
Neovascular Age-Related Macular Degeneration and GLP-1 RAs
Wajd Alkabbani, Sara J Cromer, Elisabetta Patorno
Page
of 4